Drugmakers Worry as UK Parliament Rejects Brexit Deal

The UK Parliament rejected Prime Minister Theresa May’s Brexit withdrawal agreement last week by a margin of 432-202, prompting a dismayed response from the Association of the British Pharmaceutical Industry (ABPI).

Leaving the EU without a withdrawal agreement will be “extremely challenging,” ABPI said, adding that the trade group remains focused on ensuring patient access to drugs regardless, including stockpiling and duplicating manufacturing processes.

“With time running out we hope Parliament will come together and quickly find a solution to the stalemate and reassure patients that medicines will not be disrupted come March 2019,” said ABPI Chief Executive Mike Thompson.